Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Cobenfy set to break dopamine dominance in schizophrenia treatment, says GlobalData

The FDA has recently approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy), an oral medication for the treatment of schizophrenia in adults. Diverging from the traditional dopamine-based therapies, Cobenfy is said to address the critical gaps in the current treatments by targeting muscarinic acetylcholine receptors. Its success can pave the way for broader adoption of non-dopaminergic approaches […]
Read more

One third of HCPs prioritize data privacy as the top challenge for AI in clinical practice, says GlobalData

The adoption of artificial intelligence (AI) in clinical practice is revolutionizing healthcare by improving efficiency and patient outcomes. However, with one-third of healthcare professionals identifying data privacy as the top challenge, addressing critical issues such as robust safeguards, workflow integration, and stakeholder acceptance is essential to ensure AI’s ethical implementation and long-term success, says GlobalData, […]
Read more

NAPCHD’s new guidelines signal shift in type 1 diabetes management for care home residents in UK, says GlobalData

The National Advisory Panel on Care Home Guidance (NAPCHD) has introduced a groundbreaking framework designed to transform type 1 diabetes management in care homes across England. The comprehensive guidance, “Type 1 Diabetes in Care Homes: A Practical Guide on Management,” is aimed at addressing critical challenges in managing diabetes among care home residents. By offering […]
Read more

AstraZeneca’s AZD4041 failure major blow for non-opioid medications treating opioid addiction, says GlobalData

Opioid use disorder (OUD) is a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, leading to prolonged self-administration. AstraZeneca recently terminated the development of an OUD drug, AZD4041, after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a Phase II trial. The failure of the trial […]
Read more

Biologic therapies mark progress in severe asthma treatment and remission potential, says GlobalData

Biologic therapies are revolutionizing severe asthma management by targeting specific inflammatory pathways, shifting care from symptom control to potential remission. Real-world evidence underscores their efficacy across diverse patient profiles, including those with complex asthma cases. However, barriers such as cost and accessibility persist, highlighting the urgent need for equitable healthcare solutions to ensure widespread adoption […]
Read more

Pharma dose CMOs face growth slowdown, but opportunities lie ahead, says GlobalData

Contract manufacturing revenues in the pharmaceutical finished dose sector witnessed a significant slowdown over the past financial year. Challenging market conditions, driven by drug pricing pressures, regulatory shifts, and geopolitical tensions, have reshaped the landscape, offering both hurdles and opportunities for contract manufacturing organizations (CMOs) to adapt and innovate amidst global generic shortages, reveals GlobalData, […]
Read more

Digital transformation to help accelerate drug development and discovery process, says GlobalData

Ever increasing drug discovery and development timelines is a multiscale issue causing delays in patient access to medicines and increasing costs for pharmaceutical companies. Digital transformation could streamline the process, accelerate innovation, and improve efficiency, according to a survey conducted by GlobalData, a leading data and analytics company. In a recent GlobalData’s survey, “Digital Transformation […]
Read more

Vyvgart Hytrulo gains first APAC approval in China, redefining CIDP care, says GlobalData

China’s National Medical Products Administration (NMPA) approval of Zai Lab Limited and argenx’s Vyvgart Hytrulo (efgartigimod alfa injection) marks a transformative milestone in chronic inflammatory demyelinating polyneuropathy (CIDP) care, offering the first targeted therapy for this debilitating autoimmune disorder. This approval signals a paradigm shift in CIDP management, underscoring innovation’s role in improving patient outcomes, […]
Read more

Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in China, says GlobalData

Jiangsu Hansoh Pharmaceutical Group Co Ltd has recently obtained approval for HS-20093, a B7-H3-targeted antibody-drug conjugate (ADC) to be included as Breakthrough-Therapy-Designated (BTD) Drug by the National Medical Products Administration (NMPA) of China for extensive stage small cell lung cancer (ES-SCLC) after standard first-line treatment. Against this backdrop, HS-20093 is expected to strengthen Jiangsu Hansoh […]
Read more

JAK inhibitors redefine atopic dermatitis treatment across 7MM, says GlobalData

The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM). JAK inhibitors represent a breakthrough in addressing inflammatory conditions like AD, providing a targeted approach that enhances treatment efficacy and safety, while promising new therapeutic options for diverse patient […]
Read more

Diagnosed prevalent cases of Parkinson’s disease to reach 3.15 million in 7MM by 2033, forecasts GlobalData

The diagnosed prevalent cases of Parkinson’s disease (PD) in the seven major markets (7MM*) are projected to increase from 2.64 million in 2023 to 3.15 million in 2033, with an annual growth rate (AGR) of 1.94%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Parkinson’s Disease Epidemiology Analysis and Forecast to […]
Read more

Paratek Phase IIb results highlight omadacycline’s potential to address unmet needs in NTM treatment, says GlobalData

Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic omadacycline in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease. This first-ever, randomized, placebo-controlled trial among the Mycobacterium abscessus complex (MABc) patients, highlights omadacycline’s potential to fulfill a critical unmet need within the NTM market, says GlobalData, a leading […]
Read more

Lack of skills and talent still top hinderance for digital transformation in pharma, says GlobalData

The rapid pace of technological advancement has outstripped the ability of traditional training programs to keep up, creating a significant skills gap. Without the necessary expertise, companies may struggle to integrate new systems, leading to stalled initiatives. Lack of specific skills and talents has been found to be the biggest obstacle for pharmaceutical companies in […]
Read more

UCB and Biogen’s dapirolizumab pegol paves new path for systemic lupus erythematosus treatment, says GlobalData

UCB and Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. With a novel CD40L-targeting mechanism and favorable efficacy outcomes, this therapy has the potential to challenge established SLE treatments […]
Read more

Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents, says GlobalData

Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs). With current treatments largely focused on motor symptoms, the pipeline across the seven major markets (7MM*) highlights a growing emphasis on DMTs and non-motor symptom therapies, signaling a commitment to advancing PD treatments that address the full […]
Read more

Donald Trump’s return sparks uncertainty for US pharma and healthcare industries, says GlobalData

Donald Trump’s return to the White House brings renewed uncertainty to the US pharmaceutical and healthcare industries, with potential shifts in policies affecting millions. His possible repeal or restructuring of the Affordable Care Act (ACA), coupled with plans to appoint anti-vaccine advocate Robert F. Kennedy Jr. to a prominent healthcare role, raises concerns over public […]
Read more
1 … 12 13 14 15 16 … 108